Abstracts Archive - Page 569 of 2425 - ACR Meeting Abstracts

Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
Abstract Number: 0253 • ACR Convergence 2021
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Nayimisha Balmuri¹, William Soulsby², Victoria Cooley³, Linda Gerber⁴, Erica Lawson² and Karen Onel¹, ¹Hospital for Special Surgery, New York, NY, ²University of California San Francisco, San Francisco, CA, ³Weil Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…
Abstract Number: 0252 • ACR Convergence 2021
Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis
Rajesh Kanumuri¹, Suma Balan², Vishal Marwaha², Sajitha Krishnan² and Pranav Chickermane², ¹Amrita Institute of Medical Sciences, Guntur, India, ²Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Fever is the most common presentation of systemic juvenile idiopathic arthritis (SJIA) and it is difficult to predict whether the fever is due to…
Abstract Number: 0247 • ACR Convergence 2021
Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results from the PRCSG/PRINTO JIA Real-World Registry
Nicolino Ruperto¹, Hermine Brunner², Nikolay Tzaribachev³, Ilonka Orbán⁴, Valda Staņēviča⁵, Ana Quintero del Rio⁶, Pierre Quartier⁷, Adam Huber⁸, Dan Kietz⁹, Jason Dare¹⁰, Daniel Kingsbury¹¹, T. Brent Graham¹², Ivan Foeldvari¹³, Julisa Patel¹⁴, Alyssa Dominique¹⁵, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Robert Wong¹⁶, Alberto Martini¹⁷ and Daniel Lovell¹⁸, ¹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³PRI Research, Bad Bramstedt, Germany, ⁴National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁵Riga Stradins University, Riga, Latvia, ⁶Dr. Ramon Ruiz Arnau University Hospital, Bayamόn, PR, ⁷Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ⁸Dalhousie University, Halifax, NS, Canada, ⁹Children’s Hospital of Pittsburgh, Pittsburg, PA, ¹⁰University of Arkansas for Medical Sciences, Little Rock, AR, ¹¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁴Children’s Hospital of Georgia, Augusta University Medical Center, Augusta, GA, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH
Background/Purpose: The ongoing phase 4 Pediatric Rheumatology Collaborative Study Group (PRCSG)/Paediatric Rheumatology INternational Trials Organisation (PRINTO) registry was designed to assess the long-term (up to…
Abstract Number: 0258 • ACR Convergence 2021
Developing Electronic Health Record Algorithms That Accurately Identify Patients with Juvenile Idiopathic Arthritis
Hannah Peterson¹, April Barnado² and Anna Patrick², ¹Lipscomb University College of Pharmacy, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Electronic Health Records (EHRs) store nearly all clinical data in one central location providing increased accessibility, accuracy, and security. At our institution, the Synthetic…
Abstract Number: 0257 • ACR Convergence 2021
Can We Assess Disability in Juvenile Idiopathic Arthritis with Two Simple Questions? Results from the CAPRI Registry
Meghan McPherson¹, Kristin Houghton², Nikola Surjanovic³, Thomas Loughin³, Roberta Berard⁴, Jean-Philippe Proulx-Gauthier⁵, Gaelle Chedeville⁶, Dax Rumsey⁷, Heinrike Schmeling⁸, Nadia Luca⁸, Nicole Johnson⁸, Tommy Gerschman², Paivi Miettunen⁸, Evelyn Rozenblyum⁹, Herman Tam¹⁰, Lilliam Lim⁷, Kimberly Morishita², Rosie Scuccimarri¹¹, Johannes Roth¹², Ciaran Duffy¹², Lori Tucker¹³, Brian Feldman¹⁴ and Jaime Guzman¹⁵, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Simon Fraser University, Burnaby, BC, Canada, ⁴London Health Sciences Centre, London, ON, Canada, ⁵Laval University, Québec City, QC, Canada, ⁶The Montreal Children's Hospital, Montréal, QC, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Temerty School of Medicine and Unity Health, Toronto, ON, Canada, ¹⁰Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ¹¹MgGill University, Montréal, QC, Canada, ¹²University of Ottawa, Ottawa, ON, Canada, ¹³BC Children's Hospital, Vancouver, BC, Canada, ¹⁴The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: To assess if a combination of two questions (Functional Arthritis Screening with Two Questions - FAST index) can detect and roughly estimate the degree…
Abstract Number: 0255 • ACR Convergence 2021
Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³CARRA, Durham, NC
Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…
Abstract Number: 0259 • ACR Convergence 2021
JIA Diagnoses and Trends from 2006-2019: Has the U.S. ICD-9-to-ICD-10 Transition Created Coding Artifacts?
Daniel Horton¹, Lauren Parlett², Cecilia Huang³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard⁶, Carlos Rose⁷, Kevin Haynes² and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Institute for Health, New Brunswick, NJ, ⁴Rutgers School of Social Work, New Brunswick, NJ, ⁵Rutgers School of Public Health, New Brunswick, NJ, ⁶Ernst Mario School of Pharmacy, New Brunswick, NJ, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: JIA is the most common rheumatic disease of childhood, but recent data on diagnostic trends in the US are lacking. Furthermore, the impact of…
Abstract Number: 0261 • ACR Convergence 2021
Methotrexate Withdrawal and Outcomes in Participants with Well-controlled Non-systemic JIA Within the CARRA Registry
Marinka Twilt¹, Kevin Baszis², Sarah Ringold³, Timothy Beukelman⁴, Anne Dennos⁵, Peter Shrader⁶ and Daniel Horton⁷, ¹Alberta Children's Hospital, Calgary, AB, Canada, ²Washington University School of Medicine, St Louis, MO, ³Seattle Children's Hospital, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Duke University, Durham, NC, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Methotrexate (MTX) is currently the recommended first-line conventional DMARD for the treatment of JIA with oligo- or polyarthritis. There are limited data on how…
Abstract Number: 0260 • ACR Convergence 2021
Impact on Caregivers of Patients with Juvenile Idiopathic Arthritis: A Hospital-based Study from India
Nikhil Gowda¹, Abhishek Samuel¹, Akash Yadav¹, Amita Aggarwal² and Anu Balakrishnan¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Juvenile idiopathic arthritis is a chronic disease that impacts patient's physical and mental health. Caregivers act as a bridge between physicians and patients, by…
Abstract Number: 0256 • ACR Convergence 2021
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
Tala El Tal¹, Meghan Ryan², Brian Feldman³, Catherine Bingham⁴, Jon Burnham⁵, Michelle Batthish⁶, Danielle Bullock⁷, Kerry Ferraro⁸, Mileka Gilbert⁹, Beth Gottlieb¹⁰, Julia Harris¹¹, Melissa Hazen¹², Ronald Laxer¹³, Tzielan Lee¹⁴, Daniel Lovell¹⁵, Melissa Mannion¹⁶, Laura Noonan¹⁷, Edward Oberle¹⁸, Anne Paul¹⁹, Janalee Taylor²⁰, Jennifer Weiss²¹, Cagri Yildirim-Toruner²² and Esi Morgan²³, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²University of Minnesota, Vadnais Heights, MN, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Children's Hospital, Allentown, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Minnesota, Minneapolis, MN, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Children's Mercy Kansas City, Overland Park, KS, ¹²Boston Children's Hospital, Boston, MA, ¹³SickKids, Toronto, ON, Canada, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ¹⁶University of Alabama at Birmingham, Birmingham, AL, ¹⁷Levine Children's Hospital/Carolinas Healthcare System, Charlotte, NC, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, ²⁰Cincinnati Children's Hospital, Cincinnati, OH, ²¹Hackensack University Medical Center, Hackensack, NJ, ²²Texas Children's Hospital/Baylor College of Medicine, Houston, TX, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…
Abstract Number: 0250 • ACR Convergence 2021
Is There a Need for a New Classification Criteria in Juvenile Spondyloarthritis?
Maria Martha Katsicas¹, Maria Cecilia Bertinotti² and Maria Giselle Villarreal², ¹Hospital de Pediatria J.P Garrahan, Buenos Aires, Argentina, ²Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile SpA (JSpA) involve enthesitis related arthritis (ERA), juvenile psoriatic arthritis and undifferentiated arthritis (UA) according to the ILAR criteria. Two different patterns have…
Abstract Number: 0231 • ACR Convergence 2021
Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool
Jimmy Wiegel¹, Bart Seppen¹, Marieke ter wee², Maarten Boers³, Michael Nurmohamed⁴ and wouter Bos⁵, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, location VUmc, Amsterdam, Netherlands, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁴Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁵Reade Amsterdam, Amsterdam, Netherlands
Background/Purpose: The long-term and frequent evaluation of disease activity in patients with rheumatoid arthritis (RA) leads to a large burden of planned consultations at outpatient…
Abstract Number: 0202 • ACR Convergence 2021
Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Traci Adams¹, Chad Newton¹, Lesley Davila², Kiran Batra¹, Jose Torrealba¹, Craig Glazer¹, Joan Reisch¹, Bonnie Bermas³, David Karp² and Una Makris⁴, ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³UTSouthwestern Medical Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX
Background/Purpose: We have limited knowledge of the characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. Thus,…
Abstract Number: 0139 • ACR Convergence 2021
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
Alexis Ogdie-Beatty¹, Marina Magrey², Robert Fitzsimmons¹, Shahrzad Abdollahi¹, Ana Biljan³, Christopher Saffore⁴ and Jessica Walsh⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ³Abbvie Inc., Chicago, IL, ⁴AbbVie, North Chicago, IL, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: While recommendations for the treatment of ankylosing spondylitis (AS) are largely aligned across various guidelines,1,2 there remains variability in the treatment. Patients with inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].